| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. | Chief Medical Officer | Common Stock | 36,629 | $83,617 | $2.28 | 06 Feb 2025 | Direct |
| Zentalis Pharmaceuticals, Inc. | Chief Medical Officer | Stock Option (Right to Buy) | 16,629 | 03 Feb 2025 | Direct | ||
| Trillium Therapeutics Inc. | Chief Medical Officer | Stock Option (Right to Buy) | 0 | 17 Nov 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals, Inc. | 06 Feb 2025 | 1 | +$45,656 | 4 | Chief Medical Officer | 12 Feb 2025, 17:00 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 03 Feb 2025 | 2 | $0 | 4 | Chief Medical Officer | 05 Feb 2025, 18:30 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 02 Dec 2024 | 1 | $0 | 4 | Chief Medical Officer | 03 Dec 2024, 19:02 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 13 Nov 2024 | 0 | $0 | 3 | Chief Medical Officer | 13 Nov 2024, 17:46 |
| TRIL | Trillium Therapeutics Inc. | 17 Nov 2021 | 1 | $0 | 4 | Chief Medical Officer | 19 Nov 2021, 12:25 |